
    
      A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study
      to Evaluate the Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients
      with Moderate to Severe Atopic Dermatitis
    
  